Company to Host Conference Call on Thursday, February 28, 2019 at 4:30 p.m. ETBOSTON, Feb. 28, 2019 (NewMediaWire) -- Zoom Telephonics, Inc. (“Zoom” or “the Company”) (OTCQB: ZMTP), a leading producer of cable modems and other communication products, today reported financial results for its 2018 fourth quarter and year ended December 31, 2018.Financial Highlights (Q4 and full year 2018 comparisons to prior year’s period)Q4 net sales decreased 15.8% to $7.5 million with 2018 net sales increasing 9.9% to $32.3 million.Q4 gross margin decreased to 31.6% from 36.6% with 2018 gross margin increasing to 36.0% from 34.8%.Tariffs in Q4 2018 reduced gross margins, and contributed to a decline in revenue as the Company raised some prices in an attempt to mitigate the tariffs’ negative impact on gross margins.Q4 net loss was approximately $826 thousand, or $0.05 per share, compared to a net loss of $387 thousand, or $0.03 per share, for Q4 2017. 2018 net loss was $74 thousand, or $0.00 per share, compared to a net loss of $1.37 million, or $0.09 per share, for 2017.2018 Fourth Quarter Financial ReviewNet sales for Q4 2018 decreased to $7.5 million from $8.9 million for Q4 2017. This was primarily due to reduced shelf space at one major retailer and price competition exacerbated by the Company’s attempt to increase some product prices in response to 10% China tariffs which began on September 24, 2018. The Company reacted more quickly than its competitors to the tariffs, which reduced revenues for the period. Cable modem sales declined, but the Company did experience increases in its sales of local area network and DSL products.Gross profit for Q4 2018 was $2.4 million, or 31.6% of net sales, down from $3.2 million, or 36.6% of net sales for the fourth quarter of 2017. The decrease in gross profit and gross margin was primarily due to a 10% tariff on the cost of goods for almost all its products other than ones imported into the US prior to September 24, 2018.Operating expenses for Q4 2018 were $3.1 million or 41.8% of net sales, versus $3.6 million or 40.5% of net sales for Q4 2017. Selling expenses increased approximately $58 thousand to $1.96 million for the fourth quarter of 2018, as increased Motorola trademark royalty costs and marketing funds were offset by reductions in advertising and freight costs. General and administrative expenses decreased approximately $522 thousand to $589 thousand for the fourth quarter of 2018, primarily because sales tax expenses dropped $831 thousand due to a significant one-time charge for Q4 2017. This improvement was offset by increased salary and stock option costs, and increases in legal and outside service expenses for the current quarter. Research and development expenses were $573 thousand for Q4 2018, down slightly from $577 thousand in the same period of 2017, as increased personnel costs were offset by reductions in certification expenses.Zoom reported a net loss of $826 thousand or $0.05 per share for the fourth quarter of 2018, compared to net loss of $387 thousand or $0.03 per share in the same period of 2017. 2018 Financial ReviewNet sales for year 2018 increased 9.9% to $32.3 million from $29.4 million for 2017. Sales through all but one of Zoom’s major retailers increased, but reduced sales at one retailer reduced total cable modem sales growth to just 3%. Sales of all other products combined rose over 180% primarily due to rising sales in routers, MoCA adapters, and DSL products.Gross profit in 2018 was $11.6 million or 36.0% of net sales, up from $10.2 million or 34.8% of net sales for year 2017. The increase in gross profit and gross margin was primarily due to higher net sales and a higher mix of e-tailer sales, offset somewhat by tariff-related gross margin reductions in Q4 2018.Operating expenses in 2018 were $11.6 million or 35.9% of net sales, versus $11.5 million or 38.9% of net sales in 2017. Selling expenses increased approximately $927 thousand to $8.2 million for the year, as increased Motorola trademark royalty, advertising, and personnel costs were ...

Bedminster, NJ - (NewMediaWire) - February 28, 2019 - Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market: PGC) announces the appointment of Peter D. Horst and Patrick J. Mullen to the Board of Directors of the Company and of Peapack-Gladstone Bank, effective February 28, 2019. Peter Horst is a Fortune 500 Chief Marketing Officer with 30 years of marketing leadership experience across diverse industries in consumer and business products, services and technology for market leaders such as Capital One, General Mills, US West (Century Link), Hershey and Ameritrade. He is the founder of CMO, Inc., and serves as a consultant, author, speaker, board member and advisor to senior executives on marketing strategy, messaging and growth planning. Patrick Mullen is a highly experienced financial services professional with a distinguished history of team building and effective relationship management. He is an accomplished and seasoned leader, who recently retired as the Director of Banking, State of New Jersey, for the New Jersey Department of Banking and Insurance, for which he worked over the past eight years. There, among other things, he was responsible for the examination and supervision of all state-chartered banks and credit unions and state-licensed non-bank financial institutions.“Peter and Patrick are joining our Board at the perfect time,” commented F. Duffield Meyercord, Chairman of the Board. “They both bring an elevated level of expertise and perspective in their respective fields. Peter’s extensive brand knowledge will assist us as we continue to introduce Peapack Private, our wealth management brand, to the market; and Patrick’s career with the New Jersey Department of Banking and Insurance will prove invaluable as we continue to navigate our industry’s regulatory challenges.” Peter, a resident of McLean, Virginia, is a graduate of Harvard University and Dartmouth College’s Tuck School of Business. He is a Forbes contributor and author of the best-selling book, Marketing in the #FakeNews Era. Patrick, a resident of Spring Lake, NJ, earned his Master’s Degree from Ball State University and his Bachelor of Arts from St. Francis College. His career in financial services included time spent at Chemical Bank, A.G. Becker, Inc., Kidder Peabody, Inc., Barclays Capital/BZW Securities, ABN AMRO, Inc., Alliance Capital and Sound Securities, LLC, before landing at the New Jersey Department of Banking and Insurance.ABOUT THE CORPORATIONPeapack-Gladstone Financial Corporation is a New Jersey bank holding company with total assets of $4.62 billion and assets under management and/or administration of $5.8 billion as of December 31, 2018. Founded in 1921, Peapack-Gladstone Bank is a commercial bank that provides innovative private banking services to businesses, non-profits and consumers, which help them to establish, maintain and expand their legacy. Through Peapack Private Wealth Management, and its private banking locations in Bedminster, Gladstone, Fairfield, Morristown, New Providence, Princeton and Teaneck, and its trust office in Greenville, DE, Peapack-Gladstone Bank offers an unparalleled commitment to client service through its private wealth management, commercial private banking, retail private banking and residential lending divisions, along with its online platforms. Contact: Denise M. Pace-Sanders Senior Vice President Brand and Marketing Director dpace@pgbank.com 908.470.3322 Peapack-Gladstone Bank 500 Hills Drive, Suite 300 Bedminster, NJ 07921

Merakris Therapeutics’ Lead Scientist, Sam Fagg MSc, PhD, Presents the Research Triangle Park-based Company’s Amniotic Stem Cell Co-culture Raleigh, NC - (NewMediaWire) - February 28, 2019 - Merakris Therapeutics has developed a system designed to mimic cell-cell interactions in utero to produce maximal secreted protein output that is harvested from co-cultured stem cells. Initial experiments indicate it is a strong candidate to support early-phase wound healing. The company’s innovative system mimics the amniotic environment through the co-culturing of amniotic epithelial cells with amniotic fluid cells, which generates a more robust secreted proteome than either cell type alone. The company's research has shown the product activates epithelial to mesenchymal transition, a critical step in early phase wound closure. Additionally, a complementary technique the company has developed also supports late-phase wound healing events known as re-epithelialization and keratinization. Merakris Therapeutics is developing multiple regenerative medicine approaches by using stem cell secreted factors rather than live stem cells. This focus is intended to produce solutions that are scalable, stable, and contain well-characterized target therapeutic components with various applications in disease treatment as well as potential use in cosmetic applications. The company also presented research based on its purified amniotic fluid exosome technology it is developing. The results of this research indicate that exosomes isolated from amniotic fluid promote wound healing in an in vitro assay as efficiently as total amniotic fluid. It has also developed a topical hydrogel system to provide an optimal carrier for these amniotic exosomes that shows promising results in reducing the signs of skin aging in its proof of concept studies. The company has filed multiple patents to protect its research and development discoveries.Currently, Merakris Therapeutics supplies amniotic tissue allografts to various healthcare markets and is working to develop a comprehensive market access program for its Dermacyte® Regenerative Wound Care product line to support product adoption into physician offices. Merakris Therapeutics, based in Research Triangle Park, North Carolina, is focused on researching, developing, and marketing regenerative healthcare products. Merakris is pioneering commercially scalable biotherapeutic technologies derived from stem cells that have various clinical applications. Our vision is to improve global patient care and outcomes through the pioneering and innovation of extracellular regenerative biotechnologies.Chris Broderick 919-921-8105 x 110 broderick@merakris.com

Nashville, TN - (NewMediaWire) - February 28, 2019 - LIG Assets, Inc. (OTC PINK: LIGA) (also known as the "Leader in Green Assets" or "LIGA") announces that on February 19, 2019 the Nashville City Council along with the Planning and Zoning Committee approved the change in zoning for LIGA’s “Bella Serra” development in Brentwood, Tennessee. Formerly the property was zoned AR2a but has now been re-zoned as RS10 and RM4 permitting a denser build out. With this change we will now be implementing our announced plans for the building of condos and single-family homes.LIG Assets President Marvin Baker stated, “We appreciate the thoughtful and exhaustive review of the City Council. These efforts afford LIGA the opportunity to bring to the community a truly landmark sustainable development whose aesthetic beauty will be a true asset to the community. The approval of re-zoning also adds substantial value to this important LIG Assets.” LIG Assets’ management has been fielding multiple calls from potential financing partners who are presenting far superior terms that will help expedite the development and improve the profit margins for the Company. As previously reported the projected gross sales for Bella Serra are anticipated to reach $52,470,000 upon build out of the property. The current Phase One site plan will include 90 residential units total with 10 luxury single-family homes and 80 multi-family “Lifestyle Condos.” The condo/luxury home mix in the current plan may be modified to optimize the development goals. LIGA will be finalizing the site plan to maximize the Bella Serra development for the greatest benefit of the company and our shareholders.Chairman Aric Simons added, “The re-zoning for Bella Serra is an important step forward to achieving our corporate mission of bringing sustainable, beautiful residences to the community at a market competitive price point. We shall continue to prove that sustainable building is better for families, the environment and is good business. The management of LIGA believes we have the best shareholder base for any public company on the market; we aim to reward the loyalty and enthusiasm of our investors with exponential ROI and a company each can be proud to hold in their portfolio.Bella Serra – Brentwood, Tennessee:A Luxury Mediterranean hillside resort development offering the variety of custom single-family homes and the simplistic lifestyle living of condominium villas for the most discerning buyers of luxury living at its finest. The most unique feature of these homes will be the green sustainability factor built with consideration of the environment in mind. A high quality luxury resort lifestyle community with wellness in mind while reducing carbon emissions and energy consumption to improve our quality of life. Derived from the Latin/Italian influence Bella meaning beautiful and Serra meaning views from a high place or high ridge as our community rests at one of the highest peaks in Brentwood with our ridgeline facing south into Brentwood/Franklin and the lower lined development facing toward Nashville.Bella Serra is a concept development using sustainable building products brought to us by well-known Environmentalist Robert Plarr. Bella Serra will be Nashville and Middle Tennessee’s first fully sustainable community. A new approach to residential build application using light gauge steel framing versus wood framing with our high-quality magnesium oxide panels where the combination creates a sustainable structure resistant to 185 mph winds, water and mold resistant, fire resistant to 3500 degrees with a burn rate of 5 hours before the material begins to breakdown.About LIGA Homes:LIGA Homes unique residential and commercial developments utilize specially designed and manufactured recycled "element resistant" steel framing, in addition to toxic free magnesium oxide building materials and panels that are 100% mold, fungus, termite and rot resistant and fire resistant against temperatures up to 3500 degrees Fahrenheit as well as famed environmentalist Robert ...

Washington, DC - (NewMediaWire) - February 28, 2019 - The Alliance for Regenerative Medicine (ARM) today announced the release of its 2018 Annual Data Report, offering an in-depth look at trends and metrics for the cell therapy, gene therapy, tissue engineering, and broader global regenerative medicine sector.Using data provided by ARM’s data partner Informa, curated and further analyzed by ARM’s staff, the report details industry-specific statistics and trends from more than 900 leading cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide. Key features of the report include total financings for the sector, partnerships and other deals, clinical trial information, major clinical data events, current legislative and regulatory priorities, and expert commentary from industry representatives in the U.S. and Europe.Key findings from the 2018 annual report include:Globally, companies active in gene and cell therapies and other regenerative medicines raised more than $13.3 billion in 2018, a 73% increase over 2017. The report also includes data broken out by technology and financing type. There were 1,028 clinical trials underway worldwide by year-end 2018. The report includes figures on clinical trials by phase, technology type, and indication. In Europe, the sector raised $2.2B (approximately €1.7B) in 2018, an increase of 40% over 2017, and 216 clinical trials were ongoing by year-end 2018.Industry experts expressed optimism about the future of the sector, but emphasized the need to address issues with manufacturing and scale-up as these therapies come to market, as well as the need to think creatively about financing and payment models.“We’re seeing tremendous growth in this field. 2018 financings surpassed even 2015, which was a watershed year in terms of investment for the sector,” said Janet Lambert, CEO of ARM. “But even more exciting is seeing the increasing number of patients able to access these truly transformative therapies, when before they didn’t have many, if any, options for treatment. We’re excited to see that trend continue in 2019, with additional approvals expected in the U.S. and abroad.”“ATMPs hold enormous potential value for patients, healthcare systems, and society,” said Annie Hubert, Senior Director of European Public Policy at ARM, in an overview of the European ATMP landscape included in the report. “As we go forward, ARM will continue to engage stakeholders in Europe and globally to build a supportive infrastructure for these therapies, and to ensure patients in Europe are able to access safe and effective products.”ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers, and clinical data events. The report is available to download here, with interactive data and downloadable infographics available here. Past reports, issued quarterly and annually, are available here.About The Alliance for Regenerative MedicineThe Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 300 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.Lyndsey Scull 202 213 7086 lscull@alliancerm.org

Seattle, WA - (NewMediaWire) - February 28, 2019 - CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article and exclusive CEO video interview covering Chemesis International Inc.'s (CSE: CSI) (OTCQB: CADMF) (FRA: CWAA) development of cannabis operations in Colombia. Chemesis owns a licensed cultivator there, growing on more than a thousand acres as well as in a 10,000 sqft greenhouse. The company is also building a GMP-certified production lab and extraction facility in Bogota with an eye toward both the Colombian domestic and the international export markets.Chemesis International CEO Edgar Montero discusses the company’s operations in Colombia and its presence in Puerto Rico, among other things, in Part II of CFN Media’s exclusive interview. Please use this link to see the interview: https://www.cannabisfn.com/cfnvideo/?id=A7AAqZqu. Here is a link to Part I, where Mr. Montero focuses on the company’s California production, fulfillment and distribution operations as well as its brand partnership with Jay and Silent Bob: https://www.cannabisfn.com/cfnvideo/?id=0Hy9eKzR.Cannabis industry research firm Prohibition Partners anticipates the legal cannabis industry in Latin America will reach $12.7 billion in annual sales by 2028. Uruguay led the way in the legalization movement, making recreational cannabis legal in 2013. No other countries have made that step, but several have legalized medical programs in the years since. Still, Colombia is currently the only country whose government is aggressively promoting cannabis exports, making that country the current hot spot for cannabis development.Please click here to follow Chemesis' corporate developments.Colombia’s AdvantagesIn early 2018, the Colombian government’s Drug Control Fund authorized the harvest of up to 40.5 tons of medical marijuana for export purposes. The agency estimates that at full capacity, the country could supply about 44% of the world’s current demand for medical marijuana products. The program is just getting off the ground, however, and the country is a long way from reaching that production level.The combination of a government-directed focus on exports, an ideal growing climate, and very low cost of production makes Colombia a crucial focus for near-term development. The country also boasts a population of about 6 million medical marijuana patients. One interesting aspect of the country’s laws is the general prohibition on the sale of cannabis flower. Companies operating there are necessarily focused on oils and extracted products, areas of the market that offer higher margins and are generally more attractive to consumers anyway.Please click here to follow Chemesis' corporate developments.Chemesis’ Colombian OperationsChemesis has been working closely with the Colombian government since acquiring subsidiary La Finca Interacviva-Archna Med SAS to expand its existing licensed operations in the country. La Finca is currently licensed to cultivate, produce extracted products, and distribute those products domestically. La Finca is a founding member of Colombia’s Association for the Promotion of Hemp Growing, and has established relationships with over 2,000 farming families throughout the country. It is partnered with Colombia’s largest university for research and development, and is involved in farmer education programs across the country.La Finca currently offers cannabinoid-based cosmetic products and is expanding its product lines as the company grows. La Finca anticipates achieving export capabilities upon completion of its GMP-certified production facility in Bogota, opening up a much wider market for its derivative product lines.Looking AheadColombia recently announced a renewed focus on prosecuting the cannabis black market in the country, which has only solidified the country’s legal medical program. That program is just finding its legs, and many companies establishing operations there are kind of building from scratch in a market ...

Phoenix, AZ - (NewMediaWire) - February 28, 2019 - For The Earth Corporation (the “Company” or “FTEG”) (OTCMKTS: FTEG) is proud to announce the Company’s commitment to producing and selling only CBD products derived strictly from in-house production processes. The Company has already established a diversified retail distribution footprint with both physical and e-commerce points of sale, and has begun the process of establishing its own state-of-the-art CBD extraction and production facility in Eugene, OR.“A lot of producers in the CBD industry seem to be white-labeling their products these days,” noted FTEG CEO Nelson Grist. “We plan to take a different approach. We are going to take our own raw hemp and turn it into our own pharmaceutical grade full-spectrum CBD products and sell them from our own storefront directly to the end-market consumer.” Mr. Grist has been in Eugene for the past four days interviewing leading operational candidates and consultants and examining prospective construction sites for the facility. The Company plans to control its own supply chain from cultivation through to branded product sales to customers at its kiosks, vending machines, stores, and e-commerce portals.Management believes that full vertical integration of the production process may lower production costs given the variability of CBD supplies and the potential for delays or occasional scarcity. In addition, the Company believes that consumers appreciate brands that set themselves apart from the herd by having higher quality management standards.“When we make a sale, I want to be confident that I know exactly what’s in that bottle or package, and that it’s the highest quality CBD product on the market,” continued Mr. Grist. “I want to know the ground it came out of, every ingredient in it, and who switched the equipment on where it was made.”About For The Earth CorporationFor The Earth Corporation is an emerging integrated CBD producer and retailer in the United States. The Company is in the process of establishing a vertical framework that will extend from cultivation to extraction and production to a strategic retail footprint that includes multiple locations in Las Vegas and New York featuring mall kiosks, vending machines, e-commerce, and full store locations serving both the human and pet CBD markets. Two mall leases have been signed recently in Las Vegas, with another vending machine location secured in New York City. The Company plans to expand its New York vending machine penetration by the end of 2019. In addition, the Company has begun early-stage work to establish a state-of-the-art CBD extraction and production facility in Eugene, OR.Forward-Looking StatementsExcept for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See For The Earth’s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.Safe Harbor StatementThis release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other ...

Tarrytown, NY - (NewMediaWire) - February 28, 2019 - Nightfood, Inc. (OTCQB: NGTF), the innovative company solving America’s $50 billion-dollar nighttime snacking problem, has announced that over 33,000 consumers across the country have already requested coupons for newly launched Nightfood ice cream by entering the giveaway hosted at NightfoodIceCream.com.Nightfood was voted 2019 Product of the Year in the ice cream category as chosen by over 40,000 consumers in a study conducted by consumer research giant Kantar. Management is not surprised at the level of consumer interest, and the giveaway is on track to get over 100,000 entrants as previously predicted.The ice cream is currently available in Meijer supermarket locations in the Midwest, and distribution is about to begin throughout New England and Northern California through relationships with New England Ice Cream and Wonder Ice Cream respectively.“We’re growing distribution rapidly so everybody will soon have a local store where they can use their coupon,” explained Nightfood CEO Sean Folkson. “On Facebook and Instagram, consumers are begging us to come to their cities. The rollout process takes time, but I encourage investors to pay careful attention to the enthusiasm from both the consumer base and the media. That’s what I believe will enable us to reach our distribution and revenue goals as we continue our national rollout with coming announcements.”The majority of the 33,000+ consumers will be receiving a “Buy 2, Get 1 Free” coupon, while some others will either receive a coupon for “Buy 1, Get 1 Free” or a coupon for a free pint with no purchase necessary. Once the distribution and redemption process are tested and confirmed to be running smoothly, the Company will then activate its team of high-profile influencers to start promoting the giveaway.The coupon program is being run in conjunction with PromotionPod, who has previously run successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.Leading the national rollout is Jim Christensen, Nightfood’s VP of Ice Cream Sales, who formerly held the same position for global ice cream giant Unilever, where he oversaw brands such as Breyers and Ben & Jerry’s. Management has a publicly stated goal of securing 10,000 points of distribution for Nightfood ice cream by March 31, 2020. Consumers will be notified as new distribution points begin stocking the ice cream. When Nightfood is available locally, the consumer can then print and use their coupon. About Nightfood Holdings:Nightfood Holdings, Inc. (OTC: NGTF), owns Nightfood, Inc. and MJ Munchies, Inc. On Feb 8, 2019, it was announced that Nightfood ice cream won the 2019 Product of the Year award in the ice cream category in a Kantar survey of over 40,000 consumers. With the overwhelming majority of at-home ice cream consumption occurring in the hours before bed, Nightfood’s sleep-friendly nighttime ice cream, formulated by sleep and nutrition experts, delivers benefits found in no other product on the market.Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond. Nightfood ice cream is rolling out nationally, and has recently announced distribution in the popular Meijer supermarket chain throughout the Midwest, with concentration in the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus, and Milwaukee.To enter the Nightfood® Ice Cream Giveaway, where the Company is giving away a one-year supply of Nightfood ice cream, plus a brand-new freezer to store it in, visit http://nightfoodicecream.com – each entrant gets a coupon for a free pint of ice cream (some purchase required). MJ Munchies, Inc. was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the brand name “Half-Baked”, for which they’ve successfully ...

Denver, Co - (NewMediaWire) - February 28, 2019 - American Cannabis Company, Inc. (OTCQB: AMMJ) (“ACC”), a full-service business-to-business cannabis and hemp consulting solutions provider, is pleased to announce its first industrial hemp consulting contract, under its newly launched American Hemp Services division, with The Wemp Company in the State of Alabama. The Wemp Company will be operating a 20-acre industrial hemp farm within one of the most impoverished counties in the state, with the goal to positively impact the struggling economic community. This operation will focus on processing raw hemp biomass for the production of high-quality CBD isolate. American Cannabis Company will work with this client to strategically plan and deploy farm operations by means of financial modeling, business plan creation, application technical writing and submission, farm layout design, farm roll-out and operational maintenance. ACC will also help The Wemp Company to design, build and deploy a centralized extraction facility to provide hemp processing for the hemp farmers of Alabama.In conjunction with the services that ACC will perform for The Wemp Company, American Cannabis Company will also be working with the University of Alabama’s Department of Biological Sciences to further hemp research and develop industrial hemp testing protocols to ensure cultivar quality standards and overall state compliance. Dr. Lukasz Ciesla, Assistant Professor at the Department of Biological Sciences, commented: “We are very excited to start our collaboration with The Wemp Company and help introduce hemp as a new agricultural commodity in the state of Alabama. Our lab will be analyzing plants and processed samples to check the level of non-psychoactive compounds to help select the best cultivars, and to control the quality of final products, including the CBD isolate. We are happy to contribute to the program that has a great potential to enhance the regional economic system.”Ellis Smith, Chief Development Officer of American Cannabis Company, commented: “Our company is excited to be commencing industrial hemp consulting services in this brand new market. I am personally very enthusiastic about this project as Alabama holds a special place in my heart being my home state. We are honored to be a part of this project as ACC works with The Wemp Company to launch a hemp program that will serve to positively and strongly contribute to the State’s agricultural economy. Furthermore, we are looking forward to the collaborative research efforts that will take place between ACC, The Wemp Company and the University of Alabama, as we look to advance the scientific study of hemp and the complexities of its various cannabinoids.”Calvin Weaver Jr., co-founder of The Wemp Company, said: “We are excited about the potential opportunity ahead for The Wemp Company, the people of Dallas County, the Black Belt, and our great State of Alabama. ACC’s vast knowledge and experience of the industry has proven to be an invaluable asset. Our approach in collaborating with the University of Alabama Research Lab has unlimited possibilities, and we feel this emphasizes The Wemp Company’s dedication to championing the positive impacts of industrial hemp in Alabama.”Jon Workman, Vice President of Hemp Business Development, stated: “We are thrilled to be working with The Wemp Company and accredited universities to advance the industrial hemp market in the United States. Our team is ready to work with these groups to propel the future of hemp, and we aim to establish processes and procedures that farmers from other areas can look to as standard practice for this industry. ACC will be utilizing the team’s diverse knowledge in agriculture to work with the client and educational institutions in an effort to establish a program for the certification of clean genetics to be used for large-scale agriculture. Furthermore, our group plans on hemp variety development via a world-class breeding program to target cultivar viability for specific climatic regions and soil types of North ...

Coconut Creek, FL - (NewMediaWire) - February 28, 2019 - NutraFuels, Inc., fka NutraLife Biosciences, Inc. (“the Company” or “NutraFuels”) (OTCQB: NTFU) plans to explore additional options for delivery systems for its nutraceutical and wellness products and pharmaceutical delivery systems.“We are excited to be exploring our capabilities in the life sciences space by engaging in the research and development of more formulations and enhanced delivery systems with an experienced cGMP pharmaceutical manufacturer,” said Edgar Ward, CEO and Founder of NutraFuels.The Company plans to explore these various pharmaceutical formulations and delivery systems while utilizing the valuable experience of a cGMP pharmaceutical manufacturer.The Company manufactures and distributes private label and its own branded products under its NutraHempCBD and NutraSpray brands. The Company’s product development, testing and research are conducted by four chemists under the supervision of Mr. Ward. The Company manufactures 100% of its products at its FDA registered facility in accordance with GMP standards. The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). As reported in its Form 8-K filed with the SEC on November 13, 2018, the Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. The Company’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.* These statements have not been evaluated by the Food and Drug Administration.* This product is not intended to diagnose, treat, cure or prevent any disease.Forward-Looking StatementsThis communication contains statements of a forward-looking nature about NutraFuels, Inc. (the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.Contact: NutraLife Biosciences, Inc. 6601 ...